Perspectives on syringe services programs among patients hospitalized with injection drug use-associated endocarditis: a qualitative study.
Date
2025-01
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
Background
Infective endocarditis (IE) has increased markedly among people who inject drugs (PWID). Harm reduction is a tool to help PWID improve health outcomes and mitigate IE.Objectives
To understand the knowledge, perceptions, past engagement, and planned use of harm reduction services from syringe services programs (SSPs) for PWID hospitalized with IE.Design
Qualitative study of PWID hospitalized with IE.Methods
The research team conducted semi-structured interviews with 16 participants at a large academic hospital from June 2021 to May 2022. Two study personnel coded the interviews and analyzed the data using a combination of structural codes, applied thematic analysis, and thematic comparison.Results
The majority of participants reported past experiences obtaining safe injection supplies from SSPs, and participants generally viewed SSPs as places for facilitating safer injecting practices, receiving sterile supplies, learning about harm reduction, and/or obtaining overdose reversal kits. However, some participants reported being unable to access SSPs because of their rurality, lack of SSP availability, or transportation barriers. In addition, some participants reported a lack of interest in receiving SSP information during hospitalization, believing that it would enable an undesired return to drug use, while others felt that SSP services would not be relevant for them post-hospitalization.Conclusion
Patient past and planned use of harm reduction services offered by SSPs was impacted by geographic barriers to accessibility and patient concerns that SSPs would facilitate an undesired return to drug use. Health systems have an opportunity to improve patient usage of harm reduction services post-hospitalization by improving patient education and integrating harm reduction services as tools of care.Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
McInnes, Bailey, Eunice A Okumu, Maisun M Ansary, Bayla Ostrach, Vivian H Chu, Li-Tzy Wu, Carol Golin, David L Rosen, et al. (2025). Perspectives on syringe services programs among patients hospitalized with injection drug use-associated endocarditis: a qualitative study. Therapeutic advances in infectious disease, 12. p. 20499361251353322. 10.1177/20499361251353322 Retrieved from https://hdl.handle.net/10161/33190.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Vivian Hou Chu
Dr. Chu's clinical research is focused on endocarditis (IE). She is the director of the International Collaboration on Endocarditis, a group of investigators from 78 sites in 32 countries worldwide that is dedicated to further the understanding of infective endocarditis. She serves as an officer for the International Society for Cardiovascular and Infectious Diseases. Her current research is examining the impact of oral hygiene on risk for developing infective endocarditis.
Li-Tzy Wu
Education/Training: Pre- and post-doctoral training in mental health service research, psychiatric epidemiology (NIMH T32), and addiction epidemiology (NIDA T32) from Johns Hopkins University School of Public Health (Maryland); Fellow of the NIH Summer Institute on the Design and Conduct of Randomized Clinical Trials.
Director: Duke Community Based Substance Use Disorder Research Program.
Research interests: COVID-19, Opioid misuse, Opioid overdose, Opioid use disorder, Opioid addiction prevention and treatment, Pain and addiction, Chronic diseases and substance use disorders, diabetes, pharmacy-based care models and services, medication treatment for opioid use disorder (MOUD), Drug overdose, Polysubstance use and disorders, cannabis, alcohol, tobacco, hallucinogens, stimulants, e-cigarette, SBIRT (substance use Screening, Brief Intervention, Referral to Treatment), EHR-based research and intervention, data science, psychometric analysis (IRT), epidemiology of addictions and comorbidity, behavioral health care integration, health services research (mental health disorders, substance use disorders, chronic diseases), nosology, research design, HIV risk behavior.
FUNDED Research projects (Principal Investigator [PI], Site PI, or Sub-award PI):
R03: Substance use/dependence (PI).
R21: Treatment use for alcohol use disorders (PI).
R21: Inhalant use & disorders (PI).
R01: MDMA/hallucinogen use/disorders (PI).
R01: Prescription pain reliever (opioids) misuse and use disorders (PI).
R01: Substance use disorders in adolescents (PI).
R21: CTN Substance use diagnoses & treatment (PI).
R33: CTN Substance use diagnoses & treatment (PI).
R01: Evolution of Psychopathology in the Population (ECA Duke site PI).
R01: Substance use disorders and treatment use among Asian Americans and Pacific Islanders (PI).
UG1: SBIRT in Primary Care (NIDA, PI).
UG1: TAPS Tool, Substance use screening tool validation in primary care (NIDA, PI).
UG1: NIDA CTN Mid-Southern Node (Clinical Trials Network, PI).
UG1: EHR Data Element Study (NIDA, PI).
UG1: Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder (NIDA, PI).
PCORI: INSPIRE-Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain (Site PI).
CDC R01: Evaluation of state-mandated acute and post-surgical pain-specific CDC opioid prescribing (Site PI).
Pilot: Measuring Opioid Use Disorders in Secondary Electronic Health Records Data (Carolinas Collaborative Grant: Duke PI).
R21: Developing a prevention model of alcohol use disorder for Pacific Islander young adults (Subaward PI, Investigator).
UG1: Subthreshold Opioid Use Disorder Prevention Trial (NIH HEAL Initiative) (NIDA supplement, CTN-0101, Investigator).
NIDA: A Pilot Study to Permit Opioid Treatment Program Physicians to Prescribe Methadone through Community Pharmacies for their Stable Methadone Patients (NIDA/FRI: Study PI).
UG1: Integrating pharmacy-based prevention and treatment of opioid and other substance use disorders: A survey of pharmacists and stakeholder (NIH HEAL Initiative, NIDA, PI).
UG1: NorthStar Node of the Clinical Trials Network (NIDA, Site PI).
R34: Intervention Development and Pilot Study to Reduce Untreated Native Hawaiian and Pacific Islander Opioid Use Disorders (Subaward PI, Investigator).
UG1: Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL Study) (NIDA, Site PI).
R01: Increasing access to opioid use disorder treatment by opening pharmacy-based medication units of opioid treatment programs (NIDA, PI)
R01: Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults (Subaward PI, Investigator).
R01: Understanding the short- and long-term effects of the COVID-19 pandemic on the overdose crisis (Subaward PI, Investigator).
UG1: Northstar Node of The Clinical Trials Network (Subaward PI, Investigator).
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.